Drug Type Small molecule drug |
Synonyms FHT 2344, FHT2344 |
Target |
Action inhibitors |
Mechanism SMARCA2 inhibitors(Probable global transcription activator SNF2L2 inhibitors), SMARCA4 inhibitors(Transcription activator BRG1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC23H24N6O5S2 |
InChIKeyAPLVGTKXOIMODQ-IBGZPJMESA-N |
CAS Registry2468058-90-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Uveal Melanoma | Preclinical | United States | 10 Apr 2021 |